Sign up to our newsletter for 20% OFF

Comparisons

Semax vs Selank: Two Heptapeptides Compared for Research

By NUPEPS Research TeamOctober 31, 2026

Semax vs Selank: Two Heptapeptides Compared for Research

Semax and Selank are synthetic heptapeptides from the same Moscow research program, and they are compared constantly because on paper they look like siblings: seven amino acids each, the same stabilizing Pro-Gly-Pro tail, the same institute behind them. In practice they are studied for almost opposite questions. Semax, an analogue of the ACTH (4-7) fragment, is researched mainly for cognition and neuroprotection through neurotrophic pathways such as BDNF. Selank, an analogue of the immune peptide tuftsin, is researched mainly in anxiety models through GABAergic and immunomodulatory pathways.

That single distinction, a melanocortin-derived neurotrophic tool versus a tuftsin-derived anxiolytic tool, organizes everything else in this comparison: the mechanisms, the models each compound appears in, and the way laboratories choose between them or study them together. Neither compound is approved by the FDA, and most of the evidence is preclinical. This article compares the two on origin, structure, mechanism, and published record, in research terms only.

Semax vs Selank at a Glance

AttributeSemaxSelank
Parent moleculeACTH (4-7) fragment of adrenocorticotropic hormoneTuftsin, the immunomodulatory peptide from immunoglobulin G
SequenceMet-Glu-His-Phe-Pro-Gly-ProThr-Lys-Pro-Arg-Pro-Gly-Pro
Length7 amino acids7 amino acids
Shared design featureC-terminal Pro-Gly-Pro (glyproline) tail, added to slow enzymatic breakdown
Primary research focusCognition, learning models, neuroprotectionAnxiety models, stress-response pathways
Most-studied mechanismBDNF and trkB expression in the hippocampus; NGF and GDNF modulationGABAergic gene expression; proposed allosteric GABA modulation; immune signaling
Shared secondary mechanismBoth inhibit enkephalin-degrading enzymes in human serum (reported IC50: Semax ~10 µM, Selank ~20 µM)
Regulatory statusRegistered as a medicine in Russia; not FDA-approvedRegistered as an anxiolytic in Russia; not FDA-approved
NUPEPS PEPTIDES formatsSemax 10MGSelank 10MG; Selank Semax 20MG blend

Where Did Semax and Selank Come From?

Both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, in a long-running program on regulatory oligopeptides led by Nikolai Myasoedov and colleagues. The program's design philosophy was consistent: take a short, biologically active fragment of an endogenous molecule, then extend it with proline-rich glyproline sequences that resist the enzymes which would otherwise destroy it within minutes.

Semax came first in concept. Researchers took the ACTH (4-7) fragment, Met-Glu-His-Phe, which carries the hormone's neurotropic activity on learning and attention without its steroid-releasing hormonal activity, and appended Pro-Gly-Pro. Selank applied the same trick to a completely different starting material: tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) identified in the 1970s as an immunostimulating fragment of immunoglobulin G. Extended with the same Pro-Gly-Pro tail, tuftsin's analogue became a heptapeptide with a central anxiolytic profile layered over its immune origins. One institute, one engineering trick, two unrelated biological starting points: that is the whole origin story, and it explains both the resemblance and the divergence.

What Is Semax Studied For?

Semax's literature is built around the neurotrophic system. The most-cited mechanistic work, by Dolotov and colleagues in 2006, reported that Semax increases expression of brain-derived neurotrophic factor (BDNF) and its receptor trkB in the rat hippocampus, a region central to learning and memory models. Related studies describe modulation of nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF), which together give Semax a broad neurotrophic signature rather than a single-target one.

Consistent with that signature, Semax appears most often in cognition and neuroprotection models: cerebral ischemia paradigms, where its neurotrophic and anti-inflammatory readouts are measured against injury, and learning and memory tasks in rodents. Dopaminergic and serotonergic modulation are also reported in the literature, and, like Selank, Semax inhibits enzymes that degrade enkephalins, endogenous opioid peptides involved in stress and pain pathways. What the literature does not contain is a large, independently replicated human evidence base; Semax's registered status in Russia rests on a domestic clinical literature that sits apart from the FDA and EMA record.

What Is Selank Studied For?

Selank's literature is built around anxiety models and the systems that regulate them. Its best-documented pathway is GABAergic: research published in Frontiers in Pharmacology reported that Selank alters the expression of multiple genes involved in GABAergic neurotransmission, including genes encoding GABA-A receptor subunits, and subsequent work has proposed allosteric modulation of the GABA system as a mechanism. In practical terms, the compound is studied as an anxiolytic that does not behave like a sedative in the models used, a distinction that drives much of the research interest.

Two further threads distinguish Selank from Semax. The first is enkephalin protection: Selank inhibits the enzymes that break down enkephalins, though less potently than Semax in human serum (reported IC50 of about 20 µM against Semax's 10 µM). The second is its inheritance from tuftsin: Selank retains immunomodulatory activity in the literature, including effects on cytokine balance reported in stress and infection models, which no purely GABAergic compound would predict. In a rat parkinsonism model (6-OHDA), the two peptides separated cleanly along their expected lines: Selank reduced anxiety measures, Semax did not, and neither changed motor behavior in that study.

How Do Their Mechanisms Actually Differ?

The cleanest way to hold the distinction is by primary system. Semax is a neurotrophic story: a melanocortin-derived fragment whose documented effects run through BDNF, trkB, NGF, and GDNF, which is why it is placed in cognition, learning, and neuroprotection experiments. Selank is an inhibitory-tone and immune story: a tuftsin-derived peptide whose documented effects run through GABAergic gene expression, enkephalin stabilization, and cytokine modulation, which is why it is placed in anxiety and stress-response experiments.

The overlap is real but secondary. Both peptides share the Pro-Gly-Pro tail, both inhibit enkephalin-degrading enzymes, and both are reported to touch dopaminergic and serotonergic readouts. A researcher choosing between them is therefore rarely choosing between two versions of the same tool. The choice follows the endpoint: hippocampal neurotrophic readouts point to Semax; anxiety-model and inhibitory-signaling readouts point to Selank. NUPEPS PEPTIDES' broader cognitive-research range, including Adamax 10MG and Pinealon 20MG, is catalogued on the product pages for comparison at the material level.

What Does the Evidence Base Look Like, and What Are Its Limits?

Both compounds have more published history than most research peptides, and less independent verification than their popularity suggests. The honest summary has three parts. First, the mechanistic literature is genuine and peer-reviewed, particularly for Semax's BDNF findings and Selank's GABAergic gene-expression findings. Second, that literature is concentrated: most of it comes from a small group of related laboratories, uses rodent or in vitro models, and the clinical literature behind the Russian registrations is largely Russian-language and has not been evaluated by the FDA or EMA. Third, neither compound has the multi-center, independently replicated human trial record that would support claims beyond the preclinical and exploratory level.

Researchers citing this literature in grant or paper contexts generally treat both peptides as early-stage, mechanistically interesting tools. That framing, rather than the stronger language of consumer nootropic marketing, is the one the primary sources support, and it is the framing this comparison uses throughout. For working researchers, the practical consequence is that designs using either peptide should be powered and interpreted as exploratory mechanistic work, with replication built into the plan rather than assumed from the existing record.

Why Do Researchers Study Semax and Selank Together?

Because their primary mechanisms do not collide. A design that pairs a neurotrophic endpoint with an anxiety-model endpoint can, in principle, read both from the same experiment, and the shared glyproline scaffold means the two compounds are chemically comparable in handling and stability terms. The combination is common enough that NUPEPS PEPTIDES supplies it directly as Selank Semax 20MG, alongside Semax 10MG and Selank 10MG as single compounds for designs that need the peptides separately. Whether a given study should combine them is a design question about endpoints, not a default; the single-compound literature remains the reference for attributing any observed effect.

How Do Researchers Verify Semax and Selank Material?

Small peptides leave little room for analytical sloppiness: a single wrong residue in a heptapeptide is a different molecule. Mass spectrometry should confirm each compound at its expected molecular mass and sequence-consistent identity, and reversed-phase HPLC should document purity, separating the target peptide from deletion sequences that solid-phase synthesis can leave behind. Because Semax and Selank differ entirely in sequence, a mix-up between them is exactly the kind of error a batch-specific Certificate of Analysis exists to catch.

NUPEPS PEPTIDES publishes batch Certificates of Analysis at nupeps.com/coas and tests every batch for purity, quantity, and sterility. Our guide to reading a peptide COA explains how to check the chromatogram and mass-spec sections against the compound named on the label.

Frequently Asked Questions

Are Semax and Selank the same thing?

No. They share an institute of origin, a seven-residue length, and a Pro-Gly-Pro stabilizing tail, but they are built from unrelated parent molecules and studied for different endpoints. Semax derives from the ACTH (4-7) fragment and is researched for cognition and neuroprotection; Selank derives from tuftsin and is researched in anxiety models.

Which one is studied for cognition, and which for anxiety?

Semax is the cognition-side compound: its literature centers on BDNF and trkB expression, learning models, and neuroprotection paradigms. Selank is the anxiety-side compound: its literature centers on GABAergic gene expression and anxiety models, with an immunomodulatory thread inherited from tuftsin. Both have secondary effects in the other's territory, but the primary assignments are consistent across the literature.

Are Semax and Selank approved drugs?

Both are registered as medicines in Russia (Semax as a nootropic and neuroprotectant, Selank as an anxiolytic). Neither is approved by the FDA or the EMA, and in the United States both are supplied only as research chemicals for laboratory use. The published evidence behind them is mostly preclinical.

Can Semax and Selank be studied together?

Yes, and they frequently are, because their primary mechanisms are complementary rather than overlapping: neurotrophic readouts on one side, inhibitory-signaling and anxiety-model readouts on the other. NUPEPS PEPTIDES supplies a combined Selank Semax 20MG format as well as each peptide individually, so the design can match the experimental question.

How is the purity of Semax or Selank verified?

By batch-specific Certificate of Analysis: mass spectrometry confirming identity at the expected molecular mass for the named sequence, and HPLC documenting purity of at least 99 percent for the batch supplied. Certificates for NUPEPS PEPTIDES batches are published at nupeps.com/coas.

Conclusion

Semax vs Selank is a comparison the sequences themselves settle. Two heptapeptides, one tail, two unrelated parents: the ACTH fragment became the neurotrophic, cognition-focused tool whose signature finding is hippocampal BDNF upregulation, while the tuftsin analogue became the anxiolytic-focused tool whose signature findings run through GABAergic gene expression and immune modulation. Choosing between them is choosing an endpoint, and studying them together is a deliberate design decision, not a shortcut.

What both compounds demand equally is verified material. A seven-residue peptide with one residue wrong is a different experiment, so identity by mass spectrometry, purity by HPLC, and a Certificate of Analysis for the exact batch are the working standard for either compound. This article is educational material about research compounds and is not medical advice.

Frequently asked questions

Is Semax vs Selank: Two Heptapeptides Compared for Research for human use?

No. All compounds discussed in this guide are strictly for laboratory research use only. Not for human or veterinary use.

Where can I find the Certificate of Analysis?

Certificates of Analysis are available in our COA library. Each batch is third-party tested for purity and identity.

How should research compounds be stored?

Store according to the vial label instructions. Generally, lyophilized compounds should be kept in a cool, dry place away from light. Refer to the specific product documentation for details.

All products are intended strictly for laboratory research and in-vitro use only. Not for human or veterinary consumption, diagnostic, or therapeutic use. Products are not drugs, foods, cosmetics, or dietary supplements and may not be misbranded, misused, or mislabeled.

Related articles